Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up trial of allogeneic iPS cell-derived cardiomyocyte sheet for ischemic cardiomyopathy
jRCT2053220055Active, not recruiting
- Sponsor
- Cuorips
- Start
- Jun 2022
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Human (allogeneic) iPS cell derived-cardiomyocyte sheet in ischaemic cardiomyopathy (ICM), sponsored by Cuorips. Primary endpoint: Lifetime follow-up. Started Jun 2022; status: active, not recruiting.
02
Drugs
Human (allogeneic) iPS cell derived-cardiomyocyte sheet
03
Conditions
ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on jRCT2053220055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053220055.